Edition:
United States

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

28.53USD
11 Dec 2017
Change (% chg)

$-0.60 (-2.06%)
Prev Close
$29.13
Open
$29.24
Day's High
$29.50
Day's Low
$28.48
Volume
43,774
Avg. Vol
62,991
52-wk High
$33.26
52-wk Low
$14.00

Latest Key Developments (Source: Significant Developments)

Audentes Therapeutics Q3 ‍loss per share $ 0.88​
Tuesday, 14 Nov 2017 04:01pm EST 

Nov 14 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update.Audentes Therapeutics inc qtrly ‍loss per share $ 0.88​.  Full Article

Audentes Therapeutics gets fast track designation for its muscle disorder drug
Wednesday, 27 Sep 2017 08:00am EDT 

Sept 27 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy.Audentes Therapeutics Inc - ‍preliminary data from aspiro, phase 1/2 study of AT132, expected to be available in q4 of 2017​.Audentes Therapeutics Inc - ‍AT132 has also received orphan drug designation from both fda and european medicines agency​.  Full Article

Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy
Thursday, 21 Sep 2017 08:00am EDT 

Sept 21 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy.Says ‍preliminary data from ASPIRO expected to be available in Q4 of 2017​.Says ‍Audentes plans to announce preliminary data from INCEPTUS in Q3 of 2017​.  Full Article

Audentes Therapeutics files for mixed shelf offering of up to $250 mln‍​
Tuesday, 8 Aug 2017 05:41pm EDT 

Aug 9 (Reuters) - Audentes Therapeutics Inc -:Audentes Therapeutics Inc files for mixed shelf offering of up to $250 million - sec filing‍​.  Full Article

Audentes Therapeutics qtrly loss per share $0.83
Thursday, 11 May 2017 08:00am EDT 

May 11 (Reuters) - Audentes Therapeutics Inc :Audentes therapeutics reports first quarter 2017 financial results and provides corporate update.Qtrly loss per share $ 0.83.Q1 earnings per share view $-0.92 -- Thomson Reuters I/B/E/S.Audentes therapeutics inc - research and development expenses were $14.6 million for q1 of 2017 compared to $7.9 million for same period in 2016.Audentes therapeutics inc - as of march 31, 2017, audentes had cash, cash equivalents and short-term investments of $81.7 million.Audentes therapeutics inc - current cash, cash equivalents and marketable securities are planned to fund operations into late 2019.Audentes therapeutics-on track to file inds to evaluate systemic administration of at982 for treatment of pompe disease, at307 for treatment of cpvt.  Full Article

Audentes Therapeutics says offering of 5.2 mln shares priced at $14.50/shr
Tuesday, 18 Apr 2017 08:18pm EDT 

April 18 (Reuters) - Audentes Therapeutics Inc ::Audentes Therapeutics announces pricing of public offering of common stock.Says public offering of 5.20 million common shares priced at $14.50 per share.  Full Article

Audentes Therapeutics files for common stock offering of about 4.8 mln shares
Monday, 17 Apr 2017 04:27pm EDT 

April 17 (Reuters) - Audentes Therapeutics Inc -:Files for common stock offering of about 4.8 million shares - sec filing.  Full Article

Audentes Therapeutics announces proposed public offering of common stock
Monday, 17 Apr 2017 04:01pm EDT 

April 17 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics announces proposed public offering of common stock.Says offering 4.75 million common shares.  Full Article

Audentes Therapeutics says entered into an amendment to exclusive license and collaboration agreement, dated May 3, 2016
Monday, 3 Apr 2017 05:50pm EDT 

Audentes Therapeutics Inc : Audentes Therapeutics Inc - on March 21, 2017, co entered into an amendment to exclusive license and collaboration agreement, dated May 3, 2016 .Audentes Therapeutics Inc - parties now intent to extend work plan to include additional studies - SEC filing.  Full Article

Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy
Monday, 3 Apr 2017 08:00am EDT 

Audentes Therapeutics Inc : Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy .Audentes Therapeutics Inc - preliminary data from Aspiro is expected to be available in Q4 of 2017.  Full Article

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update